EUCTR2012-002414-39-BE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 4,202
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Having T2DM and is =40 years of age.
- •2. Subject is on one of the following diabetes treatment regimens that is stable for at least 12 weeks (except for pioglitazone for at least 16 weeks) and is within the associated A1C range for that treatment regimen:
- •- An A1C =6.5 and =10.0% (=48 mmol/mol and =86 mmol/mol) on
- •diet and exercise alone (not on an AHA for =12 weeks)
- •monotherapy with metformin (MF); pioglitazone (PIO); an alpha-glucosidase inhibitor (AGI); or an SGLT2 inhibitor (SGLT2i)
- •dual combination therapy with MF, PIO, AGI or SGLT2i
- •- An A1C =7.0% and =10.0% (=53 mmol/mol and =86 mmol/mol) on monotherapy with a sulfonylurea or meglitinide
- •dual combination therapy with a sulfonylurea or a meglitinide and MF, PIO, AGI, or SGLT2i
- •- An A1C =7.0% and =10.0% (=53 mmol/mol and =86 mmol/mol) on one of the following insulin regimens (with or without metformin)
- •basal insulin (e.g., insulin glargine, insulin detemir, NPH insulin, degludec)
- •prandial insulin (e.g., regular, aspart, lispro, glulisine)
- •basal/prandial insulin regimen consisting of multiple dose insulin injections of basal and prandial insulin or the use of pre-mixed insulin (e.g., Novolog 70/30®, Novolin 70/30®, Humalog 75/25®, or Humulin 70/30®)
- •Note: A stable insulin regimen is defined as no change in the insulin regimen (i.e. type[s] of insulin) and =10% change in the total daily dose of insulin. For example, if the total daily dose of insulin is 50 U/day, doses of 45-55 U/day would be considered as stable.
- •3. Having following preexisting vascular disease:
- •(a) History of a major clinical manifestation of coronary artery disease (i.e., myocardial infarction, surgical or percutaneous [balloon and/or stent] coronary revascularization procedure, or coronary angiography showing at least one stenosis =50% in a major epicardial artery or branch vessel);
- •(b)Ischemic cerebrovascular disease, including:
- •- History of ischemic stroke
- •- History of carotid arterial disease as documented by =50% stenosis documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography, with or without symptoms of neurologic deficit.
- •(c) Atherosclerotic peripheral arterial disease, as documented by objective - amputation due to vascular disease, current symptoms of intermittent claudication confirmed by an ankle-brachial pressure index of less than 0.9 or a toe-brachial pressure index less than 0.7 or history of surgical or percutaneous revascularization procedure.
- •4.Meets one of the following criteria:
- •a. Subject is a male
- •b. Subject is a female not of reproductive potential defined as one who
- •has either:
- •(1) reached natural menopause (defined as =12 months of spontaneous amenorrhea in women >45 years of age, or =6 months of spontaneous amenorrhea with serum follicular stimulating hormone [FSH] levels in the postmenopausal range as determined by the laboratory), or
- •(2)had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least
排除标准
- •1. History of type 1 diabetes mellitus or a history of ketoacidosis or possibly having type 1 diabetes
- •2. Beeing treated with rosiglitazone, a DPP-4 inhibitor or a GLP-1 receptor agonist within the prior 12 weeks of Visit 1/Screening or previously treated with MK-3102.
- •3. Having a history of hypersensitivity to a DPP-4 inhibitor
- •4. Participation in trial with investigational compound prior 12 weeks of signing the informed consent or is not willing to refrain from participating in another trial.
- •5. Subject is on a weight loss program and is not in the maintenance phase; has been on a weight loss medication in the past 6 months; or has undergone bariatric surgery within 12 months prior to signing the informed consent.
- •6. Surgical procedure within 4 weeks prior to signing informed consent or has planned major surgery during the trial.
- •7. Treatment for =14 consecutive days or repeated courses of pharmacologic doses of corticosteroids
- •8. Treatement for hyperthyroidism or thyroid replacement therapy and has not been on a stable dose for at least 6 weeks.
- •9. Medical history of active liver disease
- •10. Human immunodeficiency virus (HIV) as assessed by medical history.
- •11. Worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months.
- •12. Poorly-controlled hypertension
- •13. History of malignancy =5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
- •14. Clinically important hematological disorder
- •15. Exclusionary laboratory values
- •16. Positive urine pregnancy test.
- •17.Subject is pregnant or breast-feeding, or is expecting to conceive during the trial, including 21 days following the last dose of blinded study medication. OR is expecting to undergo hormonal therapy in preparation to donate eggs during the period of the trial, including 21 days following the last dose of blinded study medication.
- •18. Subject is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history of drug abuse.
- •19. Subject routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per
- •week, or engages in binge drinking.
- •20. History or current evidence of condition, therapy, lab abnormality or other circumstance that
- •makes participation not in the subject’s best interest
- •might interfere with subject’s participation for the full duration of the trial, or
- •might confound the result of the trial.
- •21. Subject has donated blood products or has had phlebotomy of >300 mL within 8 weeks of signing informed consent, or intends to donate blood products within the projected duration of the trial OR received, or anticipated to receive blood products within 12 weeks of signing informed consent or within the projected duration of the trial.
- •22. Subject is unlikely to adhere to the trial procedures, keep appointments.
- •23.Symptomatic hyperglycemia that, in the investigator's opinion,
- •requires immediate initiation, adjustment, or a
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectioCrohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000886-19-ATMillennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)96
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer PaiEUCTR2005-001725-28-ATGlaxoSmithKline R & D Limited750
进行中（未招募）
1 期
A Phase 2b study to demonstrate the safety and efficacy of Tildrakizumab in patients with Active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000018188Psoriatic ArthritisEUCTR2016-003937-62-HUSUN Pharma Global FZE360
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-002414-39-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Anamorelin HCL in Patients with Non Small Cell Lung CancerCTRI/2011/091/000299Helsinn Therapeutics US Inc228